Category: Cancer

Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US

Jason Shafrin

That is the title of a new paper published in Future Oncology with co-authors Tara Graff,Savreet Bains Chawla,Monika Jun,Nicole Heaps,Abualbishr Alshreef,David Tybor,Donald C. Moore,Nadine Zawadzki, and Kathryn Spurrier. The abstract is below: Aim To quantify the time- and cost-savings to US oncology practices from using a single bispecific antibody (bsAb) for both relapsed/refractory (R/R) diffuse…

Payers and targeted therapy in oncology

Jason Shafrin

I was quoted in a recent article in Pharmaceutical Technology titled “Targeted therapies to join chemo as oncology treatment backbone“. An excerpt is below: Though payers could theoretically prioritise chemotherapy over the use of targeted treatments due to their lower price, Jason Shafrin, senior managing director of FTI’s Center for Healthcare Economics and Policy, notes…

Impact of breast cancer therapies goes beyond just health

Jason Shafrin

That is the finding from Daysal et al. (2025). We reproduce the results from an RCT showing the life-saving benefits of radiotherapy. We show radiation therapy also has economic returns: Ten years after diagnosis, treatment increases employment by 37 percent and earnings by 45 percent. Previous work has documented a substantial employment drop after a…

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States

Jason Shafrin

That is the title of a new paper out last week in Future Oncology with co-authors Kejal Jadhav, Cheryl Warren, Sabiha Quddus, Nadine Zawadzki, Daisy Yang, Andrea Damon, Kathryn Spurrier, Katharine Batt and David Wei. The abstract is below. ObjectiveTyrosine kinase inhibitors (TKIs) have transformed the prognosis of chronic myeloid leukemia (CML) into a manageable…

Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US

Jason Shafrin

That is the title of a paper published today in Future Oncology with co-authors Erin Mulvey, Kyi-Sin Than, Sanjana Muthukrishnan, Alex Mutebi, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, Diala Harb, Victor Gonzalez, Sarah Quinlan, Vardhaman Patel and Patrick Connor Johnson. The study was conducted in collaboration with the Lymphoma Research Foundation. The abstract is below:…

Imaging Utilization and Treatment Patterns of Brain Metastases in Patients with Non-Small Cell Lung Cancer

Jason Shafrin

That is the title of my most recent paper published in Clinical Lung Cancer with co-authors Mark Danese, Melissa Laurie, Beata Korytowsky, Shane Jordan, Debbie Ryan and Sukhmani K. Padda. The study abstract is below. ObjectiveThis study examined brain metastases among patients with metastatic non-small cell lung cancer (mNSCLC), characterizing prevalence, use of brain imaging,…

ISPOR 2025 Award Winners

Jason Shafrin

ISPOR recently released their award winners from their 2025 conference this May. Winners are listed below. I’m excited to announce that my podium presentation “Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection” received an award for the Best General Podium…